Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
New first-line treatment for advanced anal cancer gets EU approval
Incyte has announced that the European Commission (EC) has approved Zynyz (retifanlimab) in combination with carboplatin and paclitaxel for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). This approval is based on results from the Phase 3 POD1UM-303/InterAACT2 trial, which showed a statistically significant improvement in progression-free survival for patients receiving the Zynyz combination compared to chemotherapy alone. Zynyz is the first PD-1 immunotherapy approved in Europe for this indication in combination with platinum-based chemotherapy.